Table 4.

Clinical Response to Immunoglobulin Therapy

Patient	Dose (mg/kg)	IgG Trough (mg/dL)	Immunoglobulin Therapy	Infections Prior to Therapy (Annual Rate)	Infections Post-Therapy (Annual Rate)
2	396	1010	IVIG 35 g q4 weeks	Recurrent URI	No Infections
13	463	1390	IVIG 25 g q3 weeks	Recurrent sinus infections, frequency not recorded	Persistent recurrent sinus infections, frequency not recorded
15	334	1100	IVIG 30 g q4 weeks	Recurrent sinusitis x3, 1 URI	No infections
23	421	980	IVIG 35 g q4 weeks	3-4 sinus infections per year, URI, 1 sinusitis	Reduced frequency of infections, exact numbers not recorded
24	419	892	SCIG 10 g q weekly	Recurrent pneumonias	No infections
26	554	1130	IVIG 45 g q4 weeks	Multiple resistant MRSA skin infections	One cellulitis and one abscess
32	360	1190	IVIG 25 g q4 weeks	Recurrent sinusitis, recurrent UTI	1 sinusitis, 1 UTI
35	410	1200	SCIG 6 g qweekly	Recurrent sinusitis and URI	0 to 1 sinusitis/URI
36	400	940	fSCIG 40 g q4 weeks*	3-6 pneumonias, 3 sinus infections, 1 bronchitis	1 bronchitis
37	522	1030	IVIG 30 g q4 weeks	Chronic sinusitis x4-5	No infections
39	420	921	IVIG 30 g q4 weeks	Recurrent infections, type and frequency not recorded	No infections
43	369	1012	SCIG 12 g q10 days	Chronic sinusitis, recurrent dental, periodontal abscesses	1 bacterial infection, 2 viral infections, no abscesses
46	612	1510	SCIG 10 g qweekly	Recurrent UTI, frequency not recorded	No infections
56	390	1030	IVIG 25 g q4 weeks	Otitis media x5, pharyngitis x12, pneumonia x3, sinusitis x3, chronic MAI infection	1 otitis media, 1 pneumonia, persistent MAI infection
57	358	999	SCIG 6 g qweekly	Recurrent UTI x3 and URI x5	1 UTI and 2 URI
59	516	1110	SCIG 12 g qweekly	Recurrent pneumonia	No pneumonias
61	397	1120	IVIG 25 g q4 weeks	On IVIG for Neurologic disease	Neuropathy improved
62	800	1540	IVIG 50 g q4 weeks	On IVIG for pemphigus vulgaris	Pemphigus improved

^*fSCIG - enzyme-facilitated subcutaneous immunolgobulin.